Predictive impact of clinical factors on chemosensitivity in advanced high-grade serous ovarian carcinoma according to chemotherapy response score
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Neoadjuvant chemotherapy (NAC) response in advanced ovarian cancer can be predicted by clinical factors. Germline BRCA1/2 mutations indicate a better response (CRS3), while distant metastases suggest a poorer response (CRS1).
Area Of Science
- Gynecology
- Oncology
- Pathology
Background
- Neoadjuvant chemotherapy (NAC) is increasingly used for advanced high-grade serous ovarian carcinoma (HGSOC).
- Platinum resistance is a known complication of NAC in HGSOC.
- Identifying predictive factors for NAC response is crucial for patient selection.
Purpose Of The Study
- To evaluate the predictive impact of clinical factors on chemotherapy response score (CRS) in HGSOC patients receiving NAC.
- To identify patient subgroups likely to respond favorably to NAC.
Main Methods
- Multicenter retrospective study of 172 patients with International Federation of Gynecology and Obstetrics stage IIIC/IV HGSOC treated between 2016-2021.
- Pathological slides were scored using the CRS criteria.
- Clinical factors, including distant metastases and BRCA1/2 mutations, were analyzed for their association with CRS and survival outcomes.
Main Results
- Patients with simultaneous distant lymph node and solid organ metastases showed reduced likelihood of CRS2 (OR=0.25).
- Germline BRCA1/2 mutations were positively associated with CRS3 (OR=8.41) and predicted better prognosis.
- Higher CRS (CRS3) correlated with significantly longer progression-free survival (PFS) and overall survival (P < .001).
Conclusions
- Germline BRCA1/2 mutations are a positive predictor of CRS3 and improved survival in HGSOC patients.
- Simultaneous distant metastases predict a lower CRS (CRS1).
- CRS is a significant prognostic factor, inversely correlating with PFS and overall survival in advanced HGSOC treated with NAC.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...